Non-Hodgkin Lymphoma in Adults

We use molecular and genetic tests to diagnose non-Hodgkin lymphoma. This form of cancer arises in the body’s lymphatic system—the network of vessels, nodes, and other organs that drain excess fluid from tissues and help the body fight infections. These tests enable our hematologists, or blood cancer specialists, to create a personalized treatment plan for you. Approaches may include chemotherapy, targeted medications, stem cell transplantation, and radiation therapy. We can also determine whether you may benefit from new therapies being studied in clinical trials.

Clinical Trials and Research Studies

Phase 1/2

A Phase 1/2 Study Exploring the Safety Tolerability and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Phase 1/2

AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Phase 2

APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Phase 1/2

A Phase 1b Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine ( Rituximab) Gemcitabine Lenalidomide or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy